Over $1bn raised in venture capital funding for gene editing in 2021
Gene editing is being explored in a wide range of diseases, including single-gene rare disorders such as sickle cell disease…
By
Capital Raising
Latest in
Capital Raising
Retrotope eyes $100m raise for neurodegenerative disease platform
California-based Retrotope aims to expand its investor pool as it prepares to potentially go public in the coming years.
By
Why Covid-19 didn’t hurt tech brands’ appetite for Asian investment
Companies have reason to be sceptical about investing in Asia in general and in China in particular. But Asia investment…